Robert Driscoll
Stock Analyst at Wedbush
(2.95)
# 1,629
Out of 5,090 analysts
153
Total ratings
38.52%
Success rate
0.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $12.02 | +216.14% | 11 | Nov 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $80 | $78.51 | +1.90% | 8 | Nov 6, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $10.70 | +255.14% | 2 | Oct 20, 2025 | |
| REPL Replimune Group | Upgrades: Outperform | $4 → $18 | $10.50 | +71.51% | 7 | Oct 20, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $12.85 | +110.20% | 1 | Jul 14, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.41 | +183.69% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.01 | +497.01% | 3 | May 9, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $17.27 | -1.56% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $12.62 | -4.88% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $8.41 | +280.50% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $35.95 | +44.65% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $21.97 | +27.46% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.71 | +490.67% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $25.26 | +18.76% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.56 | +785.43% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $10.59 | +239.94% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.06 | +937.74% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.58 | +183.84% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $9.88 | +31.58% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $16.38 | +351.77% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.59 | +43.24% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.26 | +454.06% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $4.09 | +95.60% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.44 | -9.81% | 4 | May 19, 2020 |
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $12.02
Upside: +216.14%
Revolution Medicines
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $78.51
Upside: +1.90%
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $10.70
Upside: +255.14%
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $4 → $18
Current: $10.50
Upside: +71.51%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $12.85
Upside: +110.20%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.41
Upside: +183.69%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.01
Upside: +497.01%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $17.27
Upside: -1.56%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $12.62
Upside: -4.88%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $8.41
Upside: +280.50%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $35.95
Upside: +44.65%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $21.97
Upside: +27.46%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.71
Upside: +490.67%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $25.26
Upside: +18.76%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.56
Upside: +785.43%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $10.59
Upside: +239.94%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.06
Upside: +937.74%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.58
Upside: +183.84%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $9.88
Upside: +31.58%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $16.38
Upside: +351.77%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.59
Upside: +43.24%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.26
Upside: +454.06%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $4.09
Upside: +95.60%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.44
Upside: -9.81%